

## DAFTAR PUSTAKA

- Ali, M. R. *et al.* (2014) 'Aspect of thrombolytic therapy: A review', *Scientific World Journal*. Hindawi Publishing Corporation, 2014(1). doi: 10.1155/2014/586510.
- Angeli, F. *et al.*, 2015. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. *Ther Adv Cardiovasc Dis*, pp.1-13.
- Antman, E.M. & Loscalzo, J., 2015. ST-Segment Elevation Myocardial Infarction. In L.K. D, ed. *Harrison's Principles of Internal Medicine*. 19th ed. New York : McGraw-Hill Education. pp.pp. 1599-1611.
- Antman, E., Braunwald, E. & Loscalzo, J., 2010. ST Segment Elevation Myocardial Infarction. In *Harisson's Cardiovascular Medicine*. New York: Mc Graw Hill Inc.
- Baskin, J. *et al.*, 2012. Thrombolytic therapy for central venous catheter occlusion. *Haematologica*, 97(5), pp.641-50.
- Becker, R.C. & Spencer, F.A., 2004. Fibrinolytics and Platelet Antagonists. In *Fibrinolytic and Antithrombotic Therapy : Theory, Practice, and Management*. second Edition ed. United Kindom: Oxford University Press. pp.59-132.
- Bendary, A., Mohamed, S., Mohammed, M. & Taufik, W., 2017. Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen. *J Cardiovasc Thorac Res*, 9(4), pp.209-14.
- Benjamin, E. *et al.*, 2017. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. *Circulation*, pp.1-5.
- Boersma, E. *et al.* (1996) 'Early thrombolytic treatment in acute myocardial infarction.', *Lancet*, 348, pp. 1312–1313.
- Bullen, C., 2008. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. *Expert Review of Cardiovascular Therapy*, 6(6), pp.883-95.
- Bundhun, P., Janoo, G. & Meng-Hua, C., 2016. Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patients with STEMI. *Medicine*, 95(23), pp.1-9

- Candelise, L. *et al.*, 1996. Thrombolytic therapy From myocardial to cerebral infarction. *Ital. J. Neurol. Sci*, 17, pp.5-21.
- Chang, L. & Yeh, R., 2014. Evaluation and Management of ST-elevation Myocardial Infarction and Shock. *European Cardiology Review*, 9(2), pp.88-91.
- Churchhouse, A. & Ormerod, J., 2017. Infark Miokard Akut. In H. Kalim, ed. *Kardiologi dan Kelainan Vaskular*. 1st ed. Singapore: Elsevier. pp.177-93.
- Daga, L.C., Kaul, U. & Mansoor, A., 2011. Approach to STEMI and NSTEMI. *SUPPLEMENT TO JAPI • decem ber 2011 • VOL. 59*, 59, pp.19-25.
- Daley, M.J., Murthy, M.S. & Peterson, E.J., 2015. Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem. *Ther Adv Drug Saf*, 6(2), pp.57-66.
- Diprio, J. *et al.*, 2009. Acute Coronary Syndrome. In *Pharmacotherapy: A Pathophysiologic Approach*. 8th ed. United States: McGraw-Hill Education. pp.642-575.
- Duarte, G. S. *et al.* (2019) 'Morphine in acute coronary syndrome: Systematic review and meta-analysis', *BMJ Open*, 9(3), pp. 1–10. doi: 10.1136/bmjopen-2018-025232
- Fox, K., White, H.D., Gersh, B. & Opie, L.H., 2013. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In *Drugs For The Heart*. Eighth Edition ed. Philadelphia: Saunders Elsevier Inc. pp.378-87.
- Fugate, J. & Rabinstein, A.A., 2015. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. *The Neurohospitalist*, 5(3), pp.110-121.
- Ghaffari, S., Kazemi, B. & Golzari, I.G., 2011. Efficacy of a New Accelerated Streptokinase Regime in Acute Myocardial Infarction: A Double Blind Randomized Clinical Trial. *Cardiovascular Therapeutics*, pp.1-7.
- Ghaffari, S. *et al.* (2016) 'Prevalence, risk factors, and outcome of myocardial infarction with angiographically normal and near-normal coronary arteries: A systematic review and meta-analysis', *International Cardiovascular Research Journal*, 10(4), pp. 151–158.

- Gowthami, G. *et al.* (2019) 'A Study on Systemic Hypertension Influencing the Success of Thrombolysis by Streptokinase in ACS - Stemi Patients in CMCH', 18(4), pp. 89–92. doi: 10.9790/0853-1804038992.
- Gulati, R. and Gersh, B. J. (2009) 'Antithrombotic Therapy for the Prevention of Reinfarction After Reperfusion Therapy: The Price of Success', *Revista Española de Cardiología (English Edition)*. Elsevier, 62(5), pp. 474–478. doi: 10.1016/s1885-5857(09)71828-6.
- Haemostasis, A.P.G.T.L., 2013. *Practical-haemostasis*. [Online] Available at: <http://practical-haemostasis.com/Screening%20Tests/aptt> [Accessed 15 January 2018].
- Hendersoni, M., Carberry, J. & Colin, B., 2019. Targeting an Ischemic Time *Journal of the American Heart Association* , pp.1-4.
- Hermanides, R.S., Kilic, S. & Van'thof, A.W.J., 2018. Optimal pharmacological therapy in ST-elevation myocardial infarction—a review. *Neth Heart J*, 26, pp.296-310.
- Hilleman, D.E., James, T., Seals, A.A. & Marmur, J., 2007. Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction. *PHARMACOTHERAPY Volume 27, Number 11, 2007*, 27(11), pp.1559-70.
- Huang, X. *et al.*, 2016. Coagulation and Fibrinolytic activity of tenecteplase and alteplase in acute ischaemic stroke. *Stroke*, 46(12), pp.3543-46.
- Huma, S. *et al.* (2012) 'Modifiable and non-modifiable predisposing risk factors of myocardial infarction -A review', *Journal of Pharmaceutical Sciences and Research*, 4(1), pp. 1649–1653
- Ibanez, B. *et al.*, 2018. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European Heart Journal*, 39, pp.119-77.
- Iskandar, Hadi, A. & Alfridsyah, A., 2017. Faktor Resiko Terjadinya Penyakit Jantung Koroner Pada Pasien Rumah Sakit Umum Meuraxa Banda Aceh. *Jurnal AcTion: Aceh Nutrition Journal*, 2(1), pp.32-42.
- Jia, L. *et al.*, 2010. Comparison of Effects of Simvastatin Versus Atorvastatin on Oxidative Stress in Patients With Coronary Heart Disease. *Clin. Cardiol*, 33(4), pp.222-27.

- Ji, X. *et al.*, 2006. Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis. *Neurological Research*, 28, pp.46-49.
- Jinatongthai *et al.*, 2017. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. *Lancet*, 390, pp.747-59.
- Kannan, A., Chandrasekharan, R. & Radhakrishnan, V.V., 2013. Benefit of addition of clopidogrel in addition to aspirin and fibrinolytic therapy in STEMI: an Indian data. *Int J Basic Clin Pharmacol*, 2(4), pp.480-84.
- Kasper, D.L. *et al.*, 2016. ST-Segmen Elevation Miocardial Infarction. In *Harrison's Manual Of Medicine*. 19th ed. New York: McGraw-Hill Education. pp.658-67.
- Karthikeyan, G. *et al.*, 2011. Timing of adverse events during fibrinolytic therapy with streptokinase for left-sided prosthetic valve thrombosis. *J Thromb Thrombolysis*, 32, pp.146-149.
- Kemenkes, R., 2017. *Kementrian Kesehatan Republik Indonesia*. [Online] Available at: [www.depkes.go.id](http://www.depkes.go.id) [Accessed 28 July 2018].
- Kemenkes, 2018. *Hasil Utama Riskesda 2018*. Jakarta: Kementrian Kesehatan Republik Indonesia.
- Kluft, C., Sidelmann, J. & Gram, J.B., 2017. Assessing Safety of Thrombolytic Therapy. *Semin Thromb Hemost*, 43(03), pp.300-10.
- Kumat, A. & Cannon, C.P., 2009. Acute Coronary Syndromes: Diagnosis and Management, Part I. *Mayo Clin Proc*, 84(10), pp.917-38.
- Kumar, A. and Cannon, C. P. (2009) 'Acute coronary syndromes: Diagnosis and management, part ii', *Mayo Clinic Proceedings*, 84(11), pp. 1021–1036. doi: 10.4065/84.11.1021.
- Kytö, V., Sipilä, J. and Rautava, P. (2014) 'Gender, age and risk of ST segment elevation myocardial infarction', *European Journal of Clinical Investigation*, 44(10), pp. 902–909. doi: 10.1111/eci.12321.
- Langsted, A. and Nordestgaard, B. G. (2019) 'Smoking is Associated with Increased Risk of Major Bleeding: A Prospective Cohort Study',

- Thrombosis and Haemostasis*, 119(1), pp. 39–47. doi: 10.1055/s-0038-1675798.
- Leon, A.S. & Bronas, U.G., 2009. Pathophysiology of Coronary Heart Disease and Biological Mechanisms for the Cardioprotective Effects of Regular Aerobic Exercise. *American Journal of Lifestyle Medicine*, 3(5), pp.379-85.
- Lieberman, K. S. (1995) 'Markers of reperfusion after thrombolytic therapy for acute myocardial infarction', *Journal of Emergency Nursing*, 21(2), pp. 112–115. doi: 10.1016/S0099-1767(05)80009-1.
- Lim, S.H., wee, J. & Anantharaman, V., 2013. Management of STEMI. *Curr Emerg Hosp Med Rep*, 1, pp.29–36.
- Lock, C., 1999. *The ECG in Acute Myocardial Infarction - New Insights in the Thrombolytic Era, a Clinical Review*. Singapore: National University Hospital.
- Maas, A.H.E.M. & Appelman, Y.E..A., 2010. gender differences in coronary heart disease. *Netherlands Heart Journal*, 18(20), pp.598-603.
- Mahendra, S., Setianto, B.Y. & Haria, H., 2016. Prediction of Failed Fibrinolytic Using Scoring System in ST Elevation Myocardial Infarction Patients. *Acta Cardiologia Indonesiana*, 2(2), pp.39-46.
- Mega, J.L. & Morrow, D.A., 2015. ST-Elevation Myocardial Infarction: Management. In *Braunwald's Heart Disease: A Textbook of Cardiovascular*. Tenth Edition ed. Philadelphia: Saunders Elsevier Inc. pp.1095-1142..
- Mehta, R. H. *et al.* (2012) 'Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis', *American Journal of Cardiology*. Elsevier Inc., 109(3), pp. 320–326. doi: 10.1016/j.amjcard.2011.09.012.
- Nazari, J., Davidson, R., Kaplan, K. & Fintel, D., 1987. Adverse Reactions to Thrombolytic Agents Implications for Coronary Reperfusion Following Myocardial Infarction. *Medical Toxicology*, 2, pp.274-86.
- Newby, D.E., Grubb, N.R. & Bradbury, A., 2010. Cardiovascular Disease. In N.R. Colledge, B.R. Walker & B.H. Ralston, eds. *Davidson's Principle and Practice of Medicine*. 21st ed. Edinburgh: Elsevier. pp.577-98.

- O’Gara, P. T. *et al.* (2013) ‘2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary’, *Circulation*, 127(4), pp. 529–555. doi: 10.1161/cir.0b013e3182742c84.
- Oldgren, J., Wernroth, L. and Stenestrand, U. (2010) ‘Fibrinolytic therapy and bleeding complications: Risk predictors from RIKS-HIA’, *Heart*, 96(18), pp. 1451–1457. doi: 10.1136/hrt.2009.188243.
- Pandie, S. *et al.* (2016) ‘Approach to chest pain and acute myocardial infarction’, *South African Medical Journal*, 106(3), pp. 239–245. doi: 10.7196/SAMJ.2016.v106i3.10323.
- Pasceri, V., Andreotti, F. & Maseri, A., 1996. Clinical marker of thrombolytic success. *European Heart Journal*, 17, pp.35-41.
- Paudel, B., Paudel, K. & Panta, O.B., 2006. Clinical predictors of successful thrombolysis with Streptokinase and possible circadian periodicity. *Japanese Journal of Allergology*, 45(2), p.227
- PERKI (2015) ‘Pedoman Tatalaksana Sindroma Koroner Akut Edisi III’, pp. 13–14. doi: 10.1093/eurheartj/ehn416.
- Perry, D. & Grove, C., 2011. Acquired bleeding disorders. In A. Porwit, J. McCullough & W. Erber, eds. *Blood and Bone Marrow Pathology*. 2nd ed. Churchill Livingstone: Elsevier. pp.565-82.
- Picariello, C. *et al.* (2011) ‘The impact of hypertension on patients with acute coronary syndromes’, *International Journal of Hypertension*, 2011. doi: 10.4061/2011/563657.
- Pourmousavi, M. M. *et al.* (2016) ‘The impact of diabetes on electrocardiographic ST resolution and clinical outcome of acute ST elevation myocardial infarction following fibrinolytic therapy’, *Cor et Vasa*. The Czech Society of Cardiology, 58(6), pp. e584–e590. doi: 10.1016/j.crvasa.2015.11.001.
- Rathore, .V., Singh, N. & Mahat, R.K., 2018. Risk Factors for Acute Myocardial Infarction: A Review. *EJMI*, 2(1), pp.1-7.
- Reynolds, H. R. *et al.* (2007) ‘Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V’, *Archives of Internal Medicine*, 167(19), pp. 2054–2060. doi: 10.1001/archinte.167.19.2054.

- Roger, V., wita, sari & yani, 2011. Heart disease and stroke statistics 2011 update : A report from the American Heart Association. *Circulation*, 123, pp.e18-e209.
- Roshal, M., 2013. Activated Partial Thromboplastin Time. *Transfusion Medicine and Hemostatis*, pp.805-07.
- Saleem, S., Khan, A. and Shafiq, I. (2016) 'Post thrombolytic resolution of ST elevation in STEMI patients', *Pakistan Journal of Medical Sciences*, 32(1), pp. 201–205. doi: 10.12669/pjms.321.8974.
- Sampson, A.J., Paul, T. & Stouffer, G.A., 2015. Pharmacological Therapy in The Management of Acute Coronary Syndromes. In H. Wang & C. Patterson, eds. *Atherosclerosis: Risks, Mechanisms, and Therapies*. First Edition ed. NC, USA: John Wiley & Sons, Inc. pp.517-31.
- Sanchis-Gomar, F., Perez-Quilis, C., Leischik, R. & Alejandro, L., 2016. Epidemiology of coronary heart disease and acute coronary Syndrome. *Ann Transl Med*, 4(13), pp.1-12.
- Sekhar, G.R. *et al.*, 2017. A Review on Thrombolytic Therapy used in Myocardial Infarction (Streptokinase vs Tenecteplase). *Int. J. Pharm. Sci. Rev. Res*, 45(2), pp.29-32.
- Spencer, A., Pearce, M.I. & Ames, P.R., 2011. Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time. *Thrombosis Journal*, 9(16), pp.2-4.
- Stephen, J. *et al.*, 2016. Catastrophic health expenditure on acute coronary events in Asia: a prospective study. *Bulletin of the World Health Organization*, 94, pp.193-200.
- Soares, A. L. *et al.* (2010) 'Hemostatic changes in patients with type 2 diabetes mellitus', *Revista Brasileira de Hematologia e Hemoterapia*, 32(6), pp. 482–488. doi: 10.1590/S1516-84842010000600013.
- The GUSTO, I., 1993. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Eng J Med*, 329(10), pp.673– 682.
- Tumade, B., Jim, E.L. & Joseph, V.F., 2016. Prevalensi sindrom koroner akut di RSUP Prof. Dr. R. D. Kandou Manado periode 1 Januari 2014 – 31 Desember 2014. *Jurnal e-Clinic (eCl)*, 4(1), pp.223-30.

- Turpie, A. G. G. (2006) 'Fondaparinux in the management of patients with ST-elevation acute myocardial infarction', *Vascular Health and Risk Management*, 2(4), pp. 371–378. doi: 10.2147/vhrm.2006.2.4.371.
- Varma, A. *et al.* (2016) 'Clinical Markers of Reperfusion in Patients with Acute Myocardial Infarction and Its Prognostic Significance', *International Journal of Recent Surgical and Medical Sciences*, 02(02), pp. 090–095. doi: 10.5005/jp-journals-10053-0020.
- Van De Werf, F. *et al.* (2001) 'Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rt-PA', *European Heart Journal*, 22(24), pp. 2253–2261. doi: 10.1053/euhj.2001.2686.
- Vivek, L., 2017. Fibrinolytic Drug Therapy in the Management of Intravascular Thrombosis, Especially Acute Myocardial Infarction - A Review. *J of Pharmacol & Clin Res*, 2(4), pp.001-05.
- Wahyunadi, N.M.D., Sargowo, D. & Suharson, T., 2017. Perbedaan Keberhasilan Terapi Fibrinolitik Pada Penderita ST-Elevation Myocardial Infarction (STEMI) Dengan Diabetes dan Tidak Diabetes Berdasarkan Penurunan ST-Elevasi. *Jurnal Ilmu Keperawatan*, 5, pp.96-102.
- Werf, V.d., 2012. Recommendations for an efficient and safe use of fibrinolytic agents. *The Bangkok Medical Journal*, 3, pp.68-78.
- Washington, I.M. & Hoosier, G.V., 2012. Clinical Biochemistry and Hematology. *The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents*, pp.57-116.
- Yu, H. R. *et al.* (2018) 'Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction A comparative study', *Medicine (United States)*, 97(45). doi: 10.1097/MD.00000000000013010.